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Background: The NF-κB signaling pathway orchestrates many of the intricate aspects of neuroinflammation.
Astrocytic β2-adrenergic receptors have emerged as potential regulators in central nervous system inflammation
and are potential targets for pharmacological modulation. The aim of this study was to elucidate the crosstalk
between astrocytic β2-adrenergic receptors and the TNF-α induced inflammatory gene program.
Methods: Proinflammatory conditions were generated by the administration of TNF-α. Genes that are susceptible
to astrocytic crosstalk between β2-adrenergic receptors (stimulated by clenbuterol) and TNF-α were identified by
qPCR-macroarray-based gene expression analysis in a human 1321 N1 astrocytoma cell line. Transcriptional patterns
of the identified genes in vitro were validated by RT-PCR on the 1321 N1 cell line as well as on primary rat astrocytes.
In vivo expression patterns were examined by intracerebroventricular administration of clenbuterol and/or TNF-α in rats.
To examine the impact on the inflammatory cell content of the brain we performed extensive FACS analysis of rat brain
immune cells after intracerebroventricular clenbuterol and/or TNF-α administration.
Results: Parallel transcriptional patterns in vivo and in vitro confirmed the relevance of astrocytic β2-adrenergic receptors
as modulators of brain inflammatory responses. Importantly, we observed pronounced effects of β2-adrenergic receptor
agonists and TNF-α on IL-6, CXCL2, CXCL3, VCAM1, and ICAM1 expression, suggesting a role in inflammatory brain cell
homeostasis. Extensive FACS-analysis of inflammatory cell content in the brain demonstrated that clenbuterol/TNF-α
co-administration skewed the T cell population towards a double negative phenotype and induced a shift in the
myeloid brain cell population towards a neutrophilic predominance.
Conclusions: Our results show that astrocytic β2-adrenergic receptors are potent regulators of astrocytic TNF-α-activated
genes in vitro and in vivo, and ultimately modulate the molecular network involved in the homeostasis of inflammatory
cells in the central nervous system. Astrocytic β2-adrenergic receptors and their downstream signaling pathway may
serve as potential targets to modulate neuroinflammatory responses.
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Neuroinflammation constitutes an immune response against
a diverse spectrum of noxious insults in the central
nervous system (CNS), including pathogen invasion,
tissue damage, or neurodegenerative processes. In most
situations, it provides the CNS with defense and repair
mechanisms critical for its survival. However, immune* Correspondence: laureysg@hotmail.com
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stated.cells can also add insult to injury in cases of chronic
neuroinflammation or uncontrolled “auto”-immunity [1].
Astrocytes emerge as key players in the pathology of
several neurological diseases [2] and hold promise as
targets for modulating neuroinflammation in devastat-
ing diseases such as multiple sclerosis (MS) [3], amyo-
trophic lateral sclerosis [4], Parkinson’s disease [5], and
Alzheimer’s disease [6]. Moreover, astrocytes play a major
role in brain homeostasis by regulating energetic metabol-
ism and neurotransmission, secretion of neurotrophic
molecules, and expression of inflammatory molecules.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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regulated by astrocytic β2-adrenergic receptors [7].
The transcription factor NF-κB is a crucial regulator of
immunity and inflammation and has been shown to be
pivotal for astrocytic neuroinflammatory responses [8].
Targeted astrocytic NF-κB silencing reduced inflamma-
tory processes associated with spinal cord injury and
increased recovery [9]. Furthermore, in experimental al-
lergic encephalomyelitis (EAE) neuroinflammation was
reduced when NF-κB expression was downregulated in
astrocytes [10].
The anti-inflammatory effects of β2-adrenergic recep-
tors have been extensively studied in the pulmonary
system and were mainly attributed to inhibition of NF-
κB-dependent gene expression [11,12]. Furthermore, in
astrocytes, β2-adrenergic receptors appear to play a
prominent role in regulating NF-κB activity. In cultured
astrocytes, activation of β2-adrenergic receptors, through
enhancing cAMP, increased IκBα gene expression, which
in turn reduced NF-κB activation either by maintaining
NF-κB in the cytoplasm or by binding to NF-κB within
the nucleus [13].
Tumor necrosis factor-α (TNF-α) has been docu-
mented as a cytokine that plays a critical role in neuro-
inflammation linked to neurodegeneration in a number
of diseases, including MS, Parkinson’s, and Alzheimer’s
disease; many of its effects are mediated by NF-κB acti-
vation [14]. The crosstalk between β2-adrenergic recep-
tors and the NF-κB-dependent pathways in astrocytes
upon proinflammatory TNF-α treatment seems more
complex since we previously observed, in vitro, that
co-treatment of β-adrenergic agonists and TNF-α resulted
in a reduced expression of certain NF-κB‐dependent genes
(e.g., ICAM-1), but also reinforced expression of other
NF-κB‐dependent genes (e.g., IL-6) [15].
The aim of this study was to further dissect the in vitro
and in vivo crosstalk between astrocytic β2-adrenergic
receptors and NF-κB-dependent genes.
Methods
Cell culture
The human astrocytoma cell line 1321 N1 was a kind
gift from Prof. Dr. Müller (University of Bonn). 1321 N1
cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM), supplemented with 10% Fetal Calf
Serum (FCS), 100 U/mL penicillin, and 100 μg/mL strepto-
mycin (all from Invitrogen, Carlsbad, CA, USA). Cells were
maintained at 37°C in a humidified atmosphere of 5%
CO2. Cells were passaged using 0.05% (w/v) trypsin in
0.4% (w/v) EDTA.
Primary cultures of rat astrocytes were prepared from
postnatal day 1 Wistar rats. All animal procedures were
conducted in strict accordance with national guidelines
and regulations on animal experiments and approved bythe Ethics Committee on Animal Experiments of the
Faculty of Medicine and Pharmacy of the Vrije Universiteit
Brussels, Belgium. Briefly, after brain dissection, the
brain hemispheres were mechanically dissociated under
sterile conditions in phosphate buffered saline (PBS).
After a centrifugation and washing step at 1,000 rpm
for 5 min, cells were resuspended in culture medium
(DMEM+ glutaMAX+ 10% fetal bovine serum (FBS) + 1%
Pen Strep + 1% Fungizone) and residual tissue aggregates
were removed by filtration through a 70-μm pore size cell
strainer. The cells were plated in cell culture flasks (about
1.5 brains/flask) and grown in a humidified atmosphere of
5% CO2 air at 37°C. The medium was changed weekly
until a confluence of 80% was attained. Cell culture flasks
were then incubated in a shaker at 180 rpm to remove any
residual oligodendrocytes and microglia. After 6 h, the
medium was changed (discarding the non-adherent cells).
Cells were grown for another 18 h for a total of 24 h incu-
bation and medium was changed until cells had grown to
confluence. Previous studies have determined the high
degree of astrocyte purity (~95%) with this culture tech-
nique [16]. Two or three days later, cells were collected
after trypsinization and distributed at a concentration of
100,000 cells in a 6-well plate in 2 mL of culture medium
(+ 10% FCS) for RT-PCR. After adherence (48 h), cell mat-
uration was initiated by decreasing the FBS concentration
to 3% for 7 days.
In vitro treatment protocol
In vitro procedures for the human astrocytoma cell line
and primary rat astrocytes were similar except for the
dosage of TNF-α (2000 IU/mL of human TNF-α pro-
duced at the Dept. of Biomedical Research of UGent)
and 10 ng/mL rat TNF-α (Sigma-Aldrich, St. Louis, MO,
USA), clenbuterol (Sigma-Aldrich) was administered at
10 μM for human and rat astrocytes. After 2 h of starva-
tion on DMEM/1% FCS/Pen-Strep, cells were exposed
to the different stimuli for 3 h: vehicle, clenbuterol,
TNF-α, and TNF-α + clenbuterol. Cells were washed with
ice-cold PBS and resuspended in 350 μL Qiagen RNeasy
lysis buffer (RLT + β-ME) before homogenization with the
Qiashredder. Ethanol (350 μL) was added and lysates were
stored at −80°C until further processing.
Animals and surgery
Male albino Wistar rats (Charles River Laboratories,
Brussels, Belgium), weighing 260–320 g, were housed
in groups of 4 for at least 7 days following arrival in the
animal facilities. Standard environmental conditions
were ensured (temperature 21°C, humidity 60%, 10/
14 h dark/light cycle, lights on at 07:00 am). For sur-
gery, rats were anaesthetized with a mixture of keta-
mine hydrochloride and diazepam (90.5:4.5 mg/kg). A
CMA/12 guide cannula with a replaceable inner guide
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stereotactically in the left lateral ventricle. The coordi-
nates were 1.4 mm lateral and 0.9 mm posterior to
bregma and 3.5 mm ventral starting from the dura
mater [17]. Correct placement of the cannula was con-
firmed by visual identification of cerebrospinal fluid
after the insertion of the cannula. The cannula was
fixed to the skull with dental acrylic cement. After sur-
gery, the animals were housed in experimental cages
with access to water and standard laboratory chow ad
libitum to recover overnight from surgery.
In vivo treatment protocol
The guide cannula obturator was replaced with a CMA/
12 microdialysis probe (CMA Microdialysis) trimmed
down for intracerebroventricular (ICV) injection just
before the start of the experiment. Aqueous solutions
were made with purified water (Seralpur pro 90 CN,
Belgolabo, Overijse, Belgium) and filtered through a
0.2-μm membrane filter. The aqueous medium for ICV
administration, further defined as Ringer’s solution, con-
sisted of 147 mM NaCl, 1.1 mM CaCl2, and 4 mM KCl.
TNF-α and/or clenbuterol dissolved in Ringer’s solution
were administrated at a rate of 1 μL/min by means of a
CMA-100 pump for a total dose of 200 ng (10 μg/
100 μL) of TNF-α and clenbuterol for a total dose of
20 μg (10 μg/μL). Rats were euthanized 3 hours after
ICV-administration, after which the whole brain was
quickly removed and ‘snap-frozen’ in liquid nitrogen
before storage at −80°. The four experimental groups
consisted of a non-operated control group (n = 6), a
sham group with ICV Ringer’s administration (n = 6), a
clenbuterol 20 μg ICV group (n = 6), a TNF-α 200 ng
ICV group (n = 6), and a group with clenbuterol 20 μg
and TNF-α ICV co-administration (n = 6). The same
protocol was used for the FACS experiments; however,
rats were kept overnight with removal of the brain after
24 h. This time point was chosen based on previous
data showing inflammatory cell migration after 24 h in
sheep upon ICV TNF-α administration [18]. Prelimin-
ary FACS experiments in rats confirmed a TNF-α re-
sponse at 24 h. The treatment groups consisted of a
sham group with ICV Ringer’s administration (n = 6), a
clenbuterol 20 μg ICV group (n = 6), a TNF-α 200 ng
ICV group (n = 5), and a group with clenbuterol 20 μg
and TNF-α ICV co-administration (n = 5).
qPCR array
We employed a qPCR-based gene expression system that
measures the expression of 96 NF-κB dependent immuno-
logical genes (StellARray, Lonza, Basel, Switzerland). These
genes are recognized for having both κB binding sites in
the promoter and gene expression changes associated with
increased NF-κB activity. The genes included in the arrayencode diverse proteins such as cytokines, chemokines,
complement proteins, immunological receptors, and tran-
scription factors (for the complete list, see Additional file 1:
Table S1). We performed the qPCR array on three bio-
logical replicates for each of the following inductions (6 h
treatments): untreated (vehicle), isoproterenol only (Sigma-
Aldrich), TNF-α only, and isoproterenol + TNF-α. This
initial exploration was performed with isoproterenol, known
to be a mixed β1 and β2 agonist. However, the 1321 N1
cell-line expresses only the β2-subtype [19]. For confirm-
ation with RT-qPCR and rat studies the selective β2 agonist
clenbuterol was preferred excluding effects mediated by
other β-adrenergic subtypes.
RNA isolation and quantitative real-time PCR
Total RNA from rat brain was isolated using Trizol re-
agent (Invitrogen). Briefly, complete rat hemispheres
were homogenized in Trizol reagent using a tissue
homogenizer. Total RNA was isolated from these ho-
mogenates according to the manufacturer’s instruc-
tions. To remove any gDNA contaminating the RNA
samples, a DNase treatment was performed. Total RNA
from 1321 N1 cells and rat astrocytes was prepared
using the RNeasy Mini kit (Qiagen) including an on-
column DNase digestion step according to the manu-
facturer’s instructions. Reverse transcription was per-
formed on 0.5 μg of total mRNA using the Verso cDNA
kit (Thermo Fisher, Surrey, UK). For real-time cDNA
amplification we used SYBR Green Mastermix (Bio-Rad
or Roche) and the primers as stated in Additional file 1:
Table S2 of the supplementary materials. The qPCR array
and in vivo samples were analyzed using the BioRad
iCycler (Bio-Rad, Hercules, CA, USA). All in vitro samples
were analyzed on the LightCycler (Roche Applied Science,
Penzberg, Germany). A serial dilution of a cDNA mix
standard, representing a pool of cDNAs obtained from
representative samples, was used to determine the effi-
ciency of the PCR reaction and to calculate relative mRNA
inputs. Cycle threshold (CT) values for each gene were
normalized to those for hypoxanthine guanine phosphori-
bosyl transferase (HPRT).
Flow cytometric analysis of brain tissue
Isolation of brain infiltrating leukocytes was performed
as described by Beeton and Chandy [20]. Under deep
pentobarbital-anesthesia, rats underwent cardiac perfu-
sion with saline for 15 min to minimize contamination
from intravascular white blood cells. After decapitation,
the brain was quickly removed and placed in a 50 mL
tube containing ice-cold PBS. Subsequent to mechanical
dissociation, brain cells were passed through a 70-μm
cell strainer and the cell suspension was collected into a
50 mL tube on ice. After centrifugation for 8–10 min at
390 g, cells were resuspended in 20 mL PBS + 30%
Table 1 Genes showing crosstalk between the β2-adrenergic
and TNF-α triggered pathways
Fold induction versus vehicle P value
GENE ISO TNF TNF + iso ISO + TNF vs. TNF
A20 1.11 25.70 70.24 0.03
ABCB1 −1.09 18.22 17.10 0.694
C3 −1.10 22.69 8.85 0.113
CCL5 1.84 89.53 49.39 0.602
CSF2 −1.92 55.06 17.88 0.069
CXCL2 5.57 10.34 29.12 0.053
CXCL3 3.17 13.08 35.17 0.097
ICAM-1 −1.03 39.16 16.01 0.146
IL-6 2.18 1.66 253.07 0.002
LEF1 −4.75 −52.41 1.09 0.015
PSMB9 1.03 12.72 8.73 0.244
PTX3 −1.37 21.11 14.45 0.220
VCAM-1 1.07 445.48 153.39 0.510
BCL3 1.19 2.70 2.92 0.265
CSF1 −1.40 4.38 4.48 0.262
FAS 1.18 3.80 5.99 0.173
IL15 1.74 6.20 5.61 0.289
IL1RN 1.79 2.44 3.01 0.237
PLAU −2.69 12.97 16.09 0.108
TAP1 1.25 18.71 19.28 0.245
TRAF1 2.19 6.37 4.79 0.424
Marked in bold are: fold inductions significant from vehicle-treated, significant
P values for the GPR comparison of TNF + ISO vs. TNF and genes selected for
further analysis.
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This gradient was centrifuged at 390 g for 20 min at
room temperature. After removal of the fat on top of the
suspension, cells were collected from the interface and
washed twice with PBS. The cell content was then
counted and dilutions were performed in order to obtain
1–2 × 106 cells per tube for FACS analysis. After centri-
fugation at 1,400 rpm for 3 min, the supernatant was
discarded and the pellet incubated with antibody mixture
for 30 min at 4°C. Next, cells were washed in FACS buffer
(PBS/BSA/Azide) (400 μL) and then resuspended in 400 μL
of clean FACS buffer. Dilutions for FACS antibodies were
as follows: CD45 AlexaFluor 700 (BioLegend, 1:50), CD3
FITC (BioLegend, 1:100), CD4 PECy7 (BioLegend, 1:400),
CD8a PERCP (BioLegend, 1:50), CD45R PE (eBioscience,
1:50), CD161 APC (BioLegend, 1:400), CD163 FITC
(Acris, 1:20), CD11b/c APC (BioLegend, 1:50), and His45
PE (eBioscience, 1:200). For each condition, three separate
samples were prepared for T cell staining (CD45/CD3/
CD4/CD8), for lymphocyte staining (CD45/CD3/CD4/
CD8/CD45R/CD161), and for myeloid cell staining (CD45/
CD163/CD11b/c/His45), respectively. Samples were col-
lected on an LSR Fortessa flow cytometer (BD Biosciences)
and analysis of results was performed using FACSDiva
Software (BD Biosciences).
Statistical analysis
The qPCR-array data were analyzed using Global Pattern
Recognition™ software (GPR) (Lonza, Basel, Switzerland).
This software does not use standard reference genes for
normalization, but instead makes an analysis of the glo-
bal expression pattern searching for consistency in the
data. The expression level of each gene is globally posi-
tioned with respect to the expression levels of all the
other genes within an experiment and based on this an
algorithm subsequently normalizes the gene expression
data. A control for genomic DNA contamination is fur-
thermore included and a conventional ΔΔCt analysis
using 18S as a normalizer gene is additionally displayed.
For more background and validation we refer to the
2003 paper by Akilesh et al. [21]. We subsequently ana-
lyzed which genes in the isoproterenol + TNF-α condi-
tion were changed in a way that could not be predicted
by combining the information from the vehicle versus
isoproterenol and vehicle versus TNF-α comparisons.
These genes make up the two subsets that show inhibi-
tory or synergistic crosstalk as shown in Table 1. Data
for RT-qPCR and FACS analysis are presented as me-
dian ± interquartile range. qPCR and FACS data were
analyzed with a Kruskal-Wallis test followed by Dunn’s
test for pairwise comparisons (*P <0.05, **P <0.01,
and ***P <0.0001). Statistical analysis was performed with
the InStat Prism statistical package (Prism 5 for Mac
OS X, GraphPad Software, La Jolla, USA).Results
In vitro qPCR-array
We previously reported dual effects of β-agonist co-
treatment on TNF-α-induced expression of selected
prototypical NF-κB target genes [15]. To further ex-
plore this intriguing modulation of the NF-κB-dependent
gene network by β-agonists in astrocytes, we here per-
formed a qPCR-array-based gene expression analysis in
human 1321 N1 astrocytoma cells.
The full dataset of the qPCR macro-array, investigating
the expression of 96 validated NF-κB-dependent target
genes, can be found in the Additional file 1: Table S1.
An extract of these results, showing only the 21 genes
for which at least one of the treatments (iso, TNF-α, or
iso + TNF-α) resulted in significantly changed mRNA
levels (as compared to vehicle) is represented in Table 1.
As evident from this analysis, from the 96 NF-κB target
genes that were included in the qPCR array, 18 genes
were significantly upregulated and 1 gene (lymphoid
enhancer-binding factor 1, LEF1) was significantly down-
regulated upon TNF-α treatment. Isoproterenol treat-
ment significantly promoted the transcription of only
Figure 1 In vitro and in vivo data from RT-qPCR for the 1321 N1
cell line validation, in vitro rat astrocyte and in vivo experiments.
(Kruskal-Wallis with Dunn’s post-hoc analysis, *P <0.05, **P <0.01,
and ***P <0.001). Graphs represent fold expression after vehicle,
clenbuterol, TNF-α and clenbuterol with TNF-α co-administration. All data
are plotted as median with interquartile range for the following genes:
(A) A20, (B) C3, (C) CCL5, (D) CXCL2, (E) CXCL3, (F) ICAM1, (G) IL-6
and (H) VCAM1.
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(CXCL2 and CXCL3), and downregulated one (Urokinase-
type plasminogen activator (PLAU)). Upon isoproterenol/
TNF-α co-treatment, expression of two additional genes
(IL6 and IL-1 receptor agonist, IL1RN), for which the
expression was not significantly changed by either TNF-α
or β-adrenergic receptor agonist treatment alone, was
upregulated. In addition, TNF-α-induced LEF1 downregu-
lation was no longer significant upon co-treatment with
isoproterenol. Moreover, it is clear from this analysis that
there are subsets of NF-κB target genes that respond dif-
ferently to β-adrenergic receptor agonist co-treatment.
For instance, although these changes did not reach statis-
tical significance (cf. P values for TNF-α/iso co-treatment
vs. TNF-α in Table 1), the TNF-α-induced expression of
granulocyte-macrophage colony stimulating factor (CSF2),
intracellular adhesion molecule-1 (ICAM1), C3 convertase
(C3), proteasome subunit-beta type-9 (PSMB9), pentraxin-
3 (PTX3), and chemokine (C-C motif) ligand 5 (CCL5)
was inhibited, whereas that of TNF-α induced protein-3
(TNFAIP3), LEF1, CXCL2, interferon regulatory factor 1
(IRF1), CXCL3, FAS, and PLAU was enhanced upon β-
adrenergic receptor agonist co-treatment. The expression
of RELB, IL15, transporter associated with antigen pro-
cessing 1 (TAP1), CSF1, and B-cell lymphoma 3-encoded
protein (BCL3) did not change upon β-adrenergic re-
ceptor agonist co-administration as compared to the
TNF-α only set-up.
In vitro and ex vivo qPCR data
Based on the qPCR array data, we selected a number of
gene candidates for validation in 1321 N1 cells and fur-
ther in vitro and in vivo study in rats. We focused on
eight genes for which there was a clear indication for
crosstalk upon TNF/isoproterenol co-treatment (Table 1),
and for which reliable primer sets for SYBR green qPCR
amplification of the rat and human cDNAs could be
designed (A20 (TNFAIP3-gene), C3, CCL5, CXCL2, CXCL3,
ICAM1, IL-6, and VCAM1).
We found that TNF-α induced A20 mRNA expression
in vitro and in vivo, with a non-significant trend towards
suppression by clenbuterol co-administration that was
most pronounced in the primary rat astrocyte cells
(Figure 1A). Although not significant, a tendency for
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observed upon co-treatment of 1321 N1 cells, was also
apparent in vivo. The transcription of C3 by primary rat
astrocytes was, however, not significantly affected by any
of the treatments (Figure 1B). Data on the expression of
the chemokine CCL5 (RANTES) were somewhat contra-
dictory (Figure 1C). The human astrocytic cell-line showed
a non-significant trend towards an antagonism, whereas a
significant potentiation was detected in the primary rat as-
trocytes. On the other hand, in vivo clenbuterol treatment
showed a non-significant trend towards suppression of
sham-intervention- and TNF-α-mediated expression of
CCL5. For the chemokines CXCL2 and CXCL3, a synergis-
tic upregulation was observed, both in vitro and in vivo, with
clenbuterol and TNF-α co-administration (Figure 1D, E).
Figure 1G demonstrates β2-adrenergic potentiation for
the TNF-α-induced expression of IL-6 in human and
rat astrocytes both in vitro and in vivo. For the adhe-
sion molecules ICAM1 and VCAM1 (Figure 1F,H), a
TNF-α-mediated induction was observed both in vivo and
in vitro, and this effect was counteracted by clenbuterol co-
administration, an effect that was most pronounced for
VCAM1 (significances as stated in the figures).Figure 2 FACS analysis of the rat brain T cell population after TNF-α a
co-administration induces a significant increase in the proportion of CD4-C
analysis, * P <0.05). (B) Pie charts of the composition of the T cell repertoire
FACS-plots for the different treatment conditions. Color code: red for CD3+
CD3+CD4+CD8+ double positive T cells, purple for CD3+CD4-CD8- double nEx vivo FACS analysis of inflammatory cell populations
Several of the genes for which we found that the expres-
sion was affected by TNF-α/clenbuterol co-treatment
play a role in leukocyte chemotaxis. We therefore evalu-
ated, via FACS analysis, whether the distribution of
leukocyte subsets was changed in the brain during the
different treatment paradigms. Representative plots show-
ing the gating strategy for lymphocyte and myeloid line-
ages are depicted in Additional file 1: Figures S1 and S2,
respectively. A summary of all analyzed subsets can be
found in Additional file 1: Figure S3. The total percentage
of leukocytes (CD45+ cells) was not significantly changed
over the different treatment conditions. Proportions of
CD3-CD161highCD45R- (NK cells) and CD3+CD161+
(NKT cell) populations were also not significantly altered
after TNF-α and/or clenbuterol stimulation. A non-
significant trend (significant Kruskal-Wallis at P = 0.0294,
non-significant Dunn’s multiple comparison test) towards
reduced numbers of B cells (CD3-CD161-CD45R+) after
clenbuterol and TNF-α/clenbuterol co-treatment can be
noted. Within the T cell population (Figure 2), TNF-α/
clenbuterol co-administration led to a significant increase
in the CD4-CD8- double negative phenotype. The myeloidnd/or clenbuterol administration. (A) TNF-α/clenbuterol
D8- double negative T cells (Kruskal-Wallis with Dunn’s post-hoc
under the different treatment conditions. (C) Representative
CD4-CD8+ T cells, blue for CD3+CD4+CD8- T cells, green for
egative (DN) T cells.
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macrophages and an increase in neutrophils under the
influence of clenbuterol and TNF-α administration, with a
significant shift towards a neutrophilic predominance with
TNF-α/clenbuterol co-treatment (Figure 3).
Discussion
Previous publications demonstrated that activation of β2-
adrenergic receptors enhances TNF-α-induced expression
of IL-6 in both rat astrocytes and the human 1321 N1
astrocytoma cell line [15,23]. This was confirmed in our
in vitro qPCR data. Confirmation of these effects in vivo
has been lacking. We show, for the first time, by ICV
administration of both TNF-α and clenbuterol in rats, that
this also occurs in vivo. IL-6 plays an ambiguous role in
the CNS, with neurotrophic and neuroprotective effects
on the one hand, and destructive effects inducing demye-
lination and astrogliosis on the other [24]. Our results
apparently contradict a previous study suggesting a sup-
pressive effect of β2-adrenergic receptor activation on IL-6
expression in vivo, as witnessed by decreased IL-6 expres-
sion in astrocytes after locus coeruleus lesioning [25], as
well as a more recent study showing that clenbuterol
suppresses IL-6 expression in rat cortex after systemic
lipopolysaccharide (LPS) administration [26]. In the first
study there was no pro-inflammatory environment. In theFigure 3 FACS analysis of the rat brain myeloid cell population after
co-administration induces a significant increase in the proportion of neutro
Dunn’s post-hoc analysis, *P <0.05). (B) Pie charts of the composition of the my
FACS-plots for the different treatment conditions. Color code: red for macrophalatter study, in which LPS as well as clenbuterol were
administered systemically, results might have been con-
founded by indirect systemic effects which were excluded
by our ICV approach. Indeed, systemic administration of
LPS increased plasma IL-6, an effect counteracted by
intraperitoneal clenbuterol administration [27]. In addition,
although both LPS and TNF-α use NF-κB as an essential
signaling mediator, they also induce non-redundant sig-
naling cascades that might explain differences in the
outcome of crosstalk with other signaling cascades.
In accordance with the previously described anti-
inflammatory action of β-adrenergic receptor agonists,
we found that TNF-α-induced expression of ICAM1
and VCAM1 adhesion molecules was antagonized by
clenbuterol co-treatment in vitro. However, this inhibi-
tory effect could not be demonstrated in vivo. One pos-
sibility is that local inhibitory responses occur in vivo,
but that these are masked by the expression of ICAM1
and VCAM1 by cells that do not respond to the clen-
buterol treatment in the same manner as astrocytes. A
recent study documented a suppressive action of nor-
adrenaline reuptake inhibitors on CAM expression in vivo,
which was due to increased noradrenaline availability at
glial cells [28], suggesting a potential role in regulating
inflammatory cell migration across the blood brain barrier.
Our data point to the astrocytic β2-adrenergic receptors asTNF-α and/or clenbuterol administration. (A) TNF-α/clenbuterol
phils and a significant decrease in macrophages (Kruskal-Wallis with
eloid repertoire under the different treatment conditions. (C) Representative
ges (MFs), blue for neutrophils [22], green for other myeloid cells.
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One of the most remarkable findings of this study was
the susceptibility of different chemokines to TNF-α/β2-
adrenergic receptor interaction in vitro and in vivo. These
chemokines have a specific tropism for attracting immune
cells. CXCL2 mainly attracts polymorphonuclear leuko-
cytes, CXCL3 controls migration and adhesion of mono-
cytes, and CCL5 is chemotactic for T cells, eosinophils,
and basophils [29].
Although it has been previously reported that β-
adrenergic receptor activation inhibits NF-κB activity
by enhancing the expression of the NF-κB inhibitor IκB
in astrocytes [13], it is difficult to reconcile such a global
NF-κB inhibitory mechanism with our data, showing
gene-selective effects of β-agonists. In line with this, we
reported that, in 1321 N1 astrocytes, the expression of
selected NF-κB target genes was inhibited without appar-
ent changes in IκB levels, indicating additional regulatory
mechanisms must exist [15]. Multiple studies have indi-
cated that activation of the 3′-5′-cyclic adenosine mono-
phosphate (cAMP) – protein kinase A (PKA) – cAMP
response element binding protein (CREB) pathway, which
is the canonical signaling cascade induced by β-agonists,
leads to the competition of active CREB with NF-κB for
the limiting co-activator CREB-binding protein (CBP). As
CREB has a higher affinity for CBP than NF-κB, the result
of this is that the expression of NF-κB target genes, which
use CBP as a cofactor, is inhibited upon activation of
CREB [30]. Selected NF-κB target genes, such as IL-6 [15]
and CXC chemokines [31], have binding sites for both
CREB and NF-κB in their promoters and these genes
appear to be targets for potentiation, rather than inhib-
ition, by β-agonists. The exact molecular details of the
selective regulation of NF-κB target genes by β-agonists
will, however, require further study.
It has been suggested that TNF-α plays an important
role in attracting leukocytes towards the brain in diseases
as diverse as stroke, HIV-encephalitis, and MS [32-36].
Astrocytic NF-κB has been shown to play a major role in
chemokine-dependent attraction of leukocytes as a result
of traumatic brain injury [37]. In EAE experiments, it has
been demonstrated that astrocytic NF-κB modulates che-
mokine, cytokine and adhesion-molecule expression, CNS
inflammatory cell migration, and ultimately clinical out-
come [10]. Since all of the studied NF-κB dependent mol-
ecules in our experiments have pleiotropic effects on the
myriad of resident brain and immune cells, it is impossible
to predict the exact outcome of interventions on neuroin-
flammatory cell populations. It is, however, remarkable
that TNF-α/clenbuterol co-administration shifts the mye-
loid brain cell population towards a neutrophilic pre-
dominance. This correlates well with the in vitro and
in vivo potentiation of TNF-α/clenbuterol co-treatmenton astrocytic CXCL2 expression that we observed.
CXCL2 is a powerful chemo-attractant drawing neutro-
phils towards the CNS [38-40]. Astrocytes have been
identified as a source of CXCL2 involved in CNS neu-
trophil migration during early inflammatory responses
in mouse spinal cord injury [41].
Another prominent finding in our FACS data is that
TNF-α/clenbuterol co-treatment results in a shift towards
CD4-CD8- double negative (DN) T cells, expanding from
11% (sham) to 43% (TNF-α/clenbuterol) of the T cell
population. These enigmatic cells have been identified as a
marginal population in mice and humans, comprising
about 1% to 3% of the total T cell pool [42,43]. DNT
cell prevalence seems to be organ- and inflammation-
dependent (for review see [44]). This subset is thought to
act as a regulatory T cell population implicated in counter-
acting allograft rejection, graft-versus-host disease, and
autoimmune processes [45,46]. The origins and activation
mechanisms of this peculiar subset remain unclear, al-
though it has been shown that extrathymic conversion
from CD4+ T cells [47] can give rise to potent immuno-
regulatory DNT cells and CD8+ T cells that have the
ability to convert to a DN phenotype [48].
The importance of the shift in neutrophilic predomin-
ance over macrophages is more difficult to interpret.
Although crucial for clearance of infectious agents, their
role in neuroinflammatory conditions remain unclear. In
EAE, neutrophil depletion seems to have a protective
effect [49], although neutrophils are not detected in MS
lesions [50]. In neuromyelitis optica, an antibody-mediated
inflammatory condition mainly affecting spinal cord
and optic nerves, neutrophils are abundant in lesion
pathology [51]. Recent data from stroke research [52]
suggest that neutrophils may also have a neuroprotective
phenotype (the so called “N2”-phenotype) and that this
phenotype may be stimulated by the NF-κB inhibitory
pathway PPAR-γ [53]. The potential of NF-κB inhibition
in inducing neuroprotective neutrophils deserves further
attention.
To the best of our knowledge, we are the first to
describe the presence of the DNT subset in rat brain and
its upregulation by TNF-α and β2-adrenergic receptor
co-treatment. We previously reported that β2-adrenergic
receptors are selectively downregulated in astrocytes in
MS [54]. This downregulation might play a role in the
neurodegenerative aspect of the disease [2], but it remains
unclear how it can explain the inflammatory aspect of
MS. A decrease in immunoregulatory DNT cells may be a
component linking downregulation of astrocytic β2-
adrenergic receptors with neuroinflammation in MS. It
should be stressed that these findings are preliminary and
that the mechanisms behind these shifts in T cell subsets
and the potential role of β2-adrenergic receptors in regu-
lating CNS autoimmunity deserve further investigation.
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Treatment of neuroinflammation in CNS injury and de-
generation remains a therapeutic dilemma. Our in vitro
and in vivo data indicate that modulating the astrocytic
β2-adrenergic receptor tone alters NF-κB-dependent ef-
fects and the immune cell content of the CNS in proin-
flammatory conditions.
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